evidence/gaps
Cochrane · systematic review · CD012029

Bifeprunox versus placebo for schizophrenia

Chattopadhyay, A, Frey, S, Green, G · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library

SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 42.9%Very low 1 · 14.3%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

BIFEPRUNOX versus PLACEBO for schizophrenia

Population: People with schizophrenia
7 questions
OutcomeEffectEvidenceStatus / GRADE
Mental state: 1. Mean change PANSS positive subscale (lower value = good)
BIFEPRUNOX vs PLACEBO
no estimate extracted2 studies · 549 participantsLow
Downgraded: risk of bias, indirectness
Mental state: 2. Mean change PANSS negative subscale (lower value = good)
BIFEPRUNOX vs PLACEBO
no estimate extracted2 studies · 549 participantsLow
Downgraded: risk of bias, indirectness
Service use: Re‐admission
BIFEPRUNOX vs PLACEBO
no estimate extracted0 studies · 0 participantsUngraded
Global state: Deteriorated CGI
BIFEPRUNOX vs PLACEBO
RR 0.71 [0.54, 0.93]1 study · 231 participantsVery low
Downgraded: risk of bias, indirectness, publication bias
Quality of life: Important change
BIFEPRUNOX vs PLACEBO
no estimate extracted0 studies · 0 participantsUngraded
Adverse effects: Weight ‐ Total number of participants with ≥ 7% weight increase
BIFEPRUNOX vs PLACEBO
RR 1.02 [0.31, 3.33]1 study · 483 participantsModerate
Downgraded: risk of bias
Economics: Cost
BIFEPRUNOX vs PLACEBO
no estimate extracted0 studies · 0 participantsUngraded